title: Ascitic complement system in ovarian cancer.
abstract: Ovarian cancer spreads intraperitoneally and forms fluid, whereby the diagnosis and therapy often become delayed. As the complement (C) system may provide a cytotoxic effector arm for both immunological surveillance and mAb-therapy, we have characterised the C system in the intraperitoneal ascitic fluid (AF) from ovarian cancer patients. Most of the AF samples showed alternative and classical pathway haemolytic activity. The levels of C3 and C4 were similar to or in the lower normal range when compared to values in normal sera, respectively. However, elevated levels of C3a and soluble C5b-9 suggested C activation in vivo. Malignant cells isolated from the AF samples had surface deposits of C1q and C3 activation products, but not of C5b-9 (the membrane attack complex; MAC). Activation could have become initiated by anti-tumour cell antibodies that were detected in the AFs and/or by changes on tumour cell surfaces. The lack of MAC was probably due to the expression of C membrane regulators CD46, CD55 and CD59 on the tumour cells. Soluble forms of C1 inhibitor, CD59 and CD46, and the alternative pathway inhibitors factor H and FHL-1 were present in the AF at concentrations higher than in serum samples. Despite the presence of soluble C inhibitors it was possible to use AF as a C source in antibody-initiated killing of ovarian carcinoma cells. These results demonstrate that although the ovarian ascitic C system fails as an effective immunological surveillance mechanism, it could be utilised as an effector mechanism in therapy with intraperitoneally administrated mAbs, especially if the intrinsic C regulators are neutralised.
authors.affiliation: Department of Bacteriology and Immunology, Haartman Institute, University of Helsinki, FIN-00014 Helsinki, Finland. Line.Bjorge@gades.uib.no
authors.forename: L
authors.initials: L
authors.lastname: Bjørge
authors.forename: J
authors.initials: J
authors.lastname: Hakulinen
authors.forename: O K
authors.initials: OK
authors.lastname: Vintermyr
authors.forename: H
authors.initials: H
authors.lastname: Jarva
authors.forename: T S
authors.initials: TS
authors.lastname: Jensen
authors.forename: O E
authors.initials: OE
authors.lastname: Iversen
authors.forename: S
authors.initials: S
authors.lastname: Meri
mesh_terms: D000230:Adenocarcinoma / Q000097:blood / Q000503:physiopathology; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal; D001201:Ascites / Q000097:blood / Q000503:physiopathology*; D018957:CD59 Antigens / Q000097:blood; D045744:Cell Line, Tumor; D003176:Complement C3 / Q000378:metabolism; D003181:Complement C4 / Q000378:metabolism; D003165:Complement System Proteins / Q000378:metabolism*; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D007075:Immunoglobulin M / Q000097:blood; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000097:blood / Q000503:physiopathology*
chemical_list: D000911:Antibodies, Monoclonal; D018957:CD59 Antigens; D003176:Complement C3; D003181:Complement C4; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D003165:Complement System Proteins
references.citation: Am J Obstet Gynecol. 1987 Jan;156(1):263-4
references.pmid: 10681275
references.citation: J Clin Oncol. 1994 Jul;12(7):1497-515
references.pmid: 8021742
references.citation: Immunology. 1995 Jul;85(3):495-501
references.pmid: 7558140
references.citation: Int Arch Allergy Appl Immunol. 1984;74(1):63-6
references.pmid: 6608501
references.citation: Br J Cancer. 1997;75(9):1247-55
references.pmid: 9155042
references.citation: Eur J Immunol. 2004 Sep;34(9):2620-9
references.pmid: 15307194
references.citation: Nat Med. 1997 Nov;3(11):1266-70
references.pmid: 9359703
references.citation: Int J Cancer. 1998 Mar 2;75(5):663-70
references.pmid: 9495231
references.citation: Am J Obstet Gynecol. 1988 Jul;159(1):94-8
references.pmid: 3394756
references.citation: Blood. 2000 Jun 15;95(12):3900-8
references.pmid: 10845926
references.citation: Tumori. 1996 Sep-Oct;82(5):473-9
references.pmid: 9063527
references.citation: Hum Pathol. 1996 Dec;27(12):1329-35
references.pmid: 8958307
references.citation: Oncol Rep. 1998 Nov-Dec;5(6):1519-24
references.pmid: 9769398
references.citation: Mol Immunol. 1999 Sep-Oct;36(13-14):929-39
references.pmid: 10698347
references.citation: Gynecol Oncol. 1989 Mar;32(3):350-3
references.pmid: 2920956
references.citation: Am J Clin Oncol. 2001 Dec;24(6):562-5
references.pmid: 11801754
references.citation: Immunol Today. 1999 Dec;20(12):576-82
references.pmid: 10562709
references.citation: Blood. 1997 Sep 15;90(6):2188-95
references.pmid: 9310469
references.citation: Tumour Biol. 1998;19(1):1-11
references.pmid: 9422077
references.citation: Immunology. 1992 Aug;76(4):541-7
references.pmid: 1383132
references.citation: Br J Cancer. 2002 Nov 4;87(10):1119-27
references.pmid: 12402151
references.citation: Cancer. 1993 Feb 15;71(4 Suppl):1602-12
references.pmid: 8431896
references.citation: Cancer. 1994 Jun 1;73(11):2808-17
references.pmid: 7514955
references.citation: Eur J Immunol. 1994 Jul;24(7):1597-603
references.pmid: 7517877
references.citation: Int Arch Allergy Appl Immunol. 1983;71(3):219-23
references.pmid: 6602096
references.citation: Immunol Commun. 1978;7(4):441-59
references.pmid: 307530
references.citation: Semin Oncol. 1998 Jun;25(3):356-60
references.pmid: 9633848
references.citation: Springer Semin Immunopathol. 1996;18(2):243-51
references.pmid: 8908703
references.citation: Immunol Rev. 1995 Jun;145:91-122
references.pmid: 7590832
references.citation: N Engl J Med. 2001 Apr 5;344(14):1058-66
references.pmid: 11287977
references.citation: J Clin Oncol. 1998 May;16(5):1861-8
references.pmid: 9586902
references.citation: Curr Top Microbiol Immunol. 1992;178:115-40
references.pmid: 1424771
references.citation: Springer Semin Immunopathol. 1994;15(4):369-96
references.pmid: 8153873
references.citation: Int J Cancer. 1997 Jan 6;70(1):14-25
references.pmid: 8985085
references.citation: Diagn Immunol. 1984;2(1):30-5
references.pmid: 6209058
references.citation: Lab Invest. 1994 Dec;71(6):820-7
references.pmid: 7528832
references.citation: Int J Cancer. 2002 Jan 1;97(1):72-81
references.pmid: 11774246
references.citation: Clin Cancer Res. 1997 Sep;3(9):1557-64
references.pmid: 9815843
references.citation: Anticancer Res. 2000 Mar-Apr;20(2B):1061-7
references.pmid: 10810398
references.citation: Am J Pathol. 1992 May;140(5):1039-43
references.pmid: 1374587
references.citation: Cancer Immunol Immunother. 1996 Mar;42(3):185-92
references.pmid: 8640847
references.citation: Cancer. 2000 Mar 15;88(6):1432-7
references.pmid: 10717627
references.citation: J Exp Med. 1993 May 1;177(5):1409-20
references.pmid: 7683035
references.citation: Am J Pathol. 1998 Sep;153(3):845-55
references.pmid: 9736033
references.citation: J Immunol. 1993 Nov 1;151(9):4941-9
references.pmid: 7691959
references.citation: Hepatology. 1985 Jul-Aug;5(4):634-7
references.pmid: 4018735
references.citation: J Hepatol. 1991 Jan;12(1):45-9
references.pmid: 2007775
references.citation: Br J Surg. 1996 Jan;83(1):6-14
references.pmid: 8653366
references.citation: Scand J Immunol. 2000 Jun;51(6):634-41
references.pmid: 10849376
references.citation: Acta Cytol. 1988 Nov-Dec;32(6):811-5
references.pmid: 2974226
references.citation: J Immunol. 2000 Jun 1;164(11):6075-81
references.pmid: 10820293
references.citation: Ann Hematol. 2002 Jul;81(7):405-6
references.pmid: 12185515
references.citation: Gynecol Oncol. 2001 Apr;81(1):71-6
references.pmid: 11277653